Tempus AI’s (TEM) Buy Rating Reiterated at BTIG Research

BTIG Research restated their buy rating on shares of Tempus AI (NASDAQ:TEM) in a research note issued to investors on Monday,Benzinga reports. They currently have a $80.00 price objective on the stock.

Other equities research analysts also recently issued reports about the company. Needham & Company LLC reissued a “buy” rating and set a $75.00 target price on shares of Tempus AI in a research report on Friday, October 23rd. The Goldman Sachs Group initiated coverage on Tempus AI in a research note on Monday, September 21st. They set a “neutral” rating and a $75.00 price target on the stock. Guggenheim upped their price target on Tempus AI from $65.00 to $92.00 and gave the company a “buy” rating in a report on Thursday, October 1st. TD Cowen reiterated a “buy” rating on shares of Tempus AI in a research report on Wednesday, July 15th. Finally, HC Wainwright lifted their price objective on Tempus AI from $66.00 to $68.00 and gave the stock a “buy” rating in a report on Monday. Eleven investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $72.47.

Tempus AI Price Performance

NASDAQ:TEM opened at $76.61 on Monday. The stock has a market cap of $13.82 billion, a P/E ratio of -53.20 and a beta of 3.54. Tempus AI has a one year low of $40.77 and a one year high of $91.83. The company has a fifty day moving average price of $70.24 and a 200 day moving average price of $56.99. The company has a debt-to-equity ratio of 3.06, a current ratio of 3.30 and a quick ratio of 3.16.

Tempus AI (NASDAQ:TEM) last issued its quarterly earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.10. The firm had revenue of $382.49 million during the quarter, compared to the consensus estimate of $379.69 million. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The business’s revenue was up 21.6% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.22) EPS. Analysts anticipate that Tempus AI will post -1.43 earnings per share for the current year.

Insider Buying and Selling at Tempus AI

In other news, CFO James Rogers sold 26,313 shares of Tempus AI stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $60.00, for a total transaction of $1,578,780.00. Following the sale, the chief financial officer directly owned 106,024 shares in the company, valued at approximately $6,361,440. The trade was a 19.88% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Eric Lefkofsky sold 250,000 shares of the firm’s stock in a transaction dated Tuesday, September 22nd. The stock was sold at an average price of $77.47, for a total transaction of $19,367,500.00. Following the transaction, the chief executive officer owned 100,000 shares of the company’s stock, valued at approximately $7,747,000. This represents a 71.43% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,030,965 shares of company stock valued at $69,882,564 over the last quarter. 24.26% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Tempus AI

Several hedge funds and other institutional investors have recently modified their holdings of TEM. International Assets Investment Management LLC lifted its holdings in shares of Tempus AI by 3,027.6% during the third quarter. International Assets Investment Management LLC now owns 104,555 shares of the company’s stock valued at $8,563,000 after acquiring an additional 101,212 shares during the period. Partners Wealth Management LLC bought a new stake in shares of Tempus AI in the 3rd quarter worth about $241,000. China Universal Asset Management Co. Ltd. increased its position in shares of Tempus AI by 15.2% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 32,002 shares of the company’s stock worth $2,643,000 after purchasing an additional 4,227 shares in the last quarter. D.A. Davidson & CO. increased its position in shares of Tempus AI by 305.3% during the 3rd quarter. D.A. Davidson & CO. now owns 21,522 shares of the company’s stock worth $1,763,000 after purchasing an additional 16,212 shares in the last quarter. Finally, North Dakota State Investment Board acquired a new stake in shares of Tempus AI during the 3rd quarter worth about $270,000. Institutional investors own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus AI, Inc is a healthcare technology company that uses artificial intelligence and data analytics to support precision medicine. The company combines clinical, molecular and imaging data to help physicians make more informed treatment decisions and to help researchers and biopharmaceutical companies develop therapies.

Its offerings include genomic testing and analysis, such as tissue- and blood-based tests, as well as software tools designed to assist with clinical decision-making, patient matching for clinical trials and the management of healthcare data.